Moderna: positive efficacy data for vaccine
(CercleFinance.com) - Moderna announces that it has been informed by an independent data monitoring committee that its candidate vaccine against Covid-19 has reached its pre-specified statistical efficacy criterion in its phase III study.
According to the first interim analysis of this COVE study (involving more than 30,000 patients in the United States), an analysis comprising 95 participants with confirmed cases of Covid-19, the mRNA-1273 vaccine reached an efficacy of 94.5%.
Moderna intends to submit an emergency clearance request to the US FDA in the coming weeks. This request will be based on the final analysis of 151 cases and a median follow-up of over two months.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
According to the first interim analysis of this COVE study (involving more than 30,000 patients in the United States), an analysis comprising 95 participants with confirmed cases of Covid-19, the mRNA-1273 vaccine reached an efficacy of 94.5%.
Moderna intends to submit an emergency clearance request to the US FDA in the coming weeks. This request will be based on the final analysis of 151 cases and a median follow-up of over two months.
Copyright (c) 2020 CercleFinance.com. All rights reserved.